A Phase I/II, Multi-center, Randomized, Placebo-Controlled, Study Designed to Assess the Safety, Tolerability, and Pharmacokinetics of PTI-428 in Subjects With Cystic Fibrosis
Phase of Trial: Phase I/II
Latest Information Update: 11 Dec 2017
At a glance
- Drugs PTI 428 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; First in man
- Sponsors Proteostasis Therapeutics
- 11 Dec 2017 Results presented in a Proteostasis Therapeutics media release.
- 14 Nov 2017 According to a Proteostasis Therapeutics media release, the company has completed enrolment and expects preliminary data from part B of this trial in the fourth quarter of 2017. The company has commenced dosing in and expects preliminary data from the 14 days study (part C) in the first quarter of 2018.
- 19 Oct 2017 Planned End Date changed from 1 Mar 2018 to 1 Apr 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History